A166480 logo

CORESTEMCHEMON Inc. Stock Price

KOSDAQ:A166480 Community·₩42.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A166480 Share Price Performance

₩1,755.00
-12295.00 (-87.51%)
₩1,755.00
-12295.00 (-87.51%)
Price ₩1,755.00

A166480 Community Narratives

There are no narratives available yet.

Recent A166480 News & Updates

Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price Plunge

Aug 19
Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price Plunge

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is Lacking

Apr 14
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is Lacking

Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?

Feb 20
Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Dec 09
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

Nov 01
Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

Sep 24
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

CORESTEMCHEMON Inc. Key Details

₩24.8b

Revenue

₩27.4b

Cost of Revenue

-₩2.5b

Gross Profit

₩7.9b

Other Expenses

-₩10.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-428.09
Gross Margin
-10.15%
Net Profit Margin
-41.99%
Debt/Equity Ratio
105.6%

CORESTEMCHEMON Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Low risk and slightly overvalued.

3 Risks
0 Rewards

About A166480

Founded
2003
Employees
36
CEO
Kyung-Suk Kim
WebsiteView website
www.corestem.com

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

South Korean Market Performance

  • 7 Days: 3.3%
  • 3 Months: 13.9%
  • 1 Year: 32.6%
  • Year to Date: 44.6%
The market has climbed 3.3% in the last 7 days, lead by the Information Technology sector with a gain of 7.0%. As for the past 12 months, the market is up 33%. Looking forward, earnings are forecast to grow by 24% annually. Market details ›